Summary

A Phase II, randomized, double-blind, placebo-controlled, 2-part study to evaluate the safety, tolerability, pharmacokinetics, clinical response, and antiviral activity of orally administered study drug regimens in hospitalized or non-hospitalized infants and children aged 28 days to 24 months infected with RSV (respiratory syncytial virus).

Register to download

Collaboration Advances Small Pharma Company’s Pediatric Development Plan to First-in-Pediatrics RSV Study

You may also be interested in: